Cystic Fibrosis

CF Clinical Advisory Board

Highly respected key opinion leaders in cystic fibrosis

Synedgen’s Clinical Advisory Board includes internationally respected leaders in cystic fibrosis to guide our clinical development. This team advises appropriate design of drug administration, critiques drug development plans and trial design, and also assesses the potential impact of the drug for strategic partners and investors.

Dr. Jim Chmiel is Clinical Director of Pediatric Pulmonology at UH Rainbow Babies and Children’s Hospital, and Associate Professor of Pediatrics at Case Western Reserve University School of Medicine. His clinical expertise and research involves understanding the inflammatory response of the lung, particularly as it relates to asthma and cystic fibrosis, and the impact of anti-inflammatory therapeutics upon this response.

Dr. John Clancy is Professor of Pediatrics at the University of Cincinnati, Tom Boat Chair in Cystic Fibrosis Clinical and Translational Research, and Research Director, Division of Pulmonary Medicine at Cincinnati Children’s Hospital. He specializes in cystic fibrosis, airway cellular biology, and CFTR regulation. Dr. Clancy has served in several leadership roles at University of Alabama, Cincinnati Children’s Hospital, and within the international cystic fibrosis community.

Dr. Bonnie Ramsey is the past Director of the Center for Clinical and Translational Research at Seattle Children’s Research Institute. Dr. Ramsey is co-PI of the University of Washington Institute for Translational Health Sciences, which provides extensive clinical research infrastructure at Seattle Children’s Hospital. She is Professor and Vice Chair for research in the Department of Pediatrics, and holds the Endowed Chair in Cystic Fibrosis at the University of Washington School of Medicine. Her career has focused on clinical care and research in the field of cystic fibrosis. She is internationally recognized for her work in developing new therapies for patients with cystic fibrosis and bringing them to market, most notably Tobramycin. She remains active in the CF Therapeutics Development Network that directs clinical trials throughout the United States.

Dr. Steven Rowe is Professor of Pulmonary Medicine and Physiology & Biophysics at the University of Alabama at Birmingham. He currently serves as Director of the UAB CF Transition Clinic for adolescent young adults with cystic fibrosis, and Director of the CFF Therapeutics Development Network, Center for CFTR Detection. Dr. Rowe specializes in developing new treatments for cystic fibrosis, and maintains expertise in the design and conduct of clinical trials targeting the basic CF defect. Dr. Rowe has an interest in biomarkers of CF, including ion transport and the relation between mucus stasis and inflammation. He also directs an International Mucus Clearance Consortium, including basic and translational scientists charged with improving the mechanistic understanding of the mucus clearance defect in cystic fibrosis, and novel means to monitor the process.